Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Recurrent or Metastatic Endometrial Cancer
NCT03099499Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2017
- Primary completion
- Sep 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in endometrial cancer (EC), sponsored by Fox Chase Cancer Center. Started Jun 2017; status: terminated.
02
Drugs
dordaviprone
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03099499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099499.